Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

RHYTHM Study Reveals Link Between Total AF Burden and Stroke Risk
News | ECG Monitoring Services | May 17, 2018
May 17, 2018 — A new study published in JAMA Cardiology used the Zio continuous cardiac monitoring system by iRhythm to...
Itamar Medical Launches SleePath for AFib Patients at Heart Rhythm 2018
Technology | Patient Monitors | May 16, 2018
May 16, 2018 — Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care...
Link Found Between Post-Traumatic Stress, Increased Risk of AFib. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new...
Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular...
First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018
May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and...
New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018
May 11, 2018 — A new study finds that integrating two separate clinical risk score models more accurately helps...
Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods
News | ECG Monitoring Services | May 09, 2018
May 9, 2018 – Medicalgorithmics S.A. will present the results of a large study evaluating online versus offline...
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first...
The Abbott Advisor HD Grid Mapping Catheter, Sensor Enabled, allows high density electro mapping for transcatheter EP cardiac ablation procedures.
Technology | EP Mapping and Imaging Systems | May 03, 2018
May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD Grid...
Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018
April 12, 2018 — Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic...
Depression Linked to Increased Atrial Fibrillation Risk
News | Atrial Fibrillation | March 27, 2018
March 27, 2018 — Depression may increase the risk for atrial fibrillation, the most common heart rhythm disorder that...
Self-Applied Chest Patch Catches Atrial Fibrillation More Quickly Than Usual Care
News | Wearables | March 19, 2018
March 19, 2018 — For people at heightened risk for atrial fibrillation (AFib), a common heart rhythm disorder that also...
ECG on Smartwatch Accurately Detects AFib
News | ACC | March 15, 2018
March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately display...
ACC 2018 highlights and trends.  #acc.18, #ACC, #ACC2018
Feature | ACC | January 31, 2018
The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating. In...
Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant...